



The Alliance for Better Bone Health

5 September 2007

Mr Mark Taylor
Chair, Appeal Panel
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London WC1V 6NA

Dear Mr Taylor

Final Appraisal Determinations: primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women

Thank you for your letter of 15th August responding to our letter of 9th July setting out the grounds of our Appeal.

We attach revised versions of our 9th July letters (one in response to the secondary prevention FAD, one in response to the primary prevention FAD) with numbered paragraphs as requested. These revised versions also accommodate your suggestion that one of our points of appeal under Ground 1 (that relating to the inclusion of DXA scanning in the cost-effectiveness analysis) should be moved to Ground 2.

You indicate that misleading incompleteness in section 3.1 of the secondary prevention FAD could be evidence of perversity. We argue that this is the case because such incompleteness mis-states the role of the technologies in relation to the remit of the appraisal (which specifically includes the prevention of osteoporotic fractures, to which BMD is only one contributory factor). We would be grateful for your confirmation that this is a valid ground for appeal.

Yours sincerely

[REDACTED]
Senior Manager – HTA, sanofi-aventis
On behalf of the Alliance for Better Bone Health
T: [REDACTED]
E: [REDACTED]